Akruti Nirman Limited is a leading player in the Real Estate Sector in India, involved in the creation of various sector specific infrastructure such as IT Parks, BT Parks, Commercial and Residential properties. It is presently involved in the development of India's largest BT Park in Gujarat with an aim to provide the impetus for a Biotech led Socio-Economic revolution in the State of Gujarat, by giving access to the most modern technologies & infrastructure, which ultimately fosters entrepreneurship, innovation and growth. The Park comprises Built to suit plots ( plug & play ), Loaded wet labs, Bioincubation centre, Animal House, pilot plant facility, microbiological labs, tissue culture labs, green house, logistic centre etc and also will house a residential/commercial township with modern amenities.

Almac employs over 2,000 people throughout our extensive facilities in Europe and North America. Our integrated development services range from: Comprehensive genomic and bioinformatics services; Cancer genomics contract research; Route design & synthesis of APIs (including potent, peptide and chiral compounds); Synthesis and formulation of labelled compounds (pre-clinical and clinical) Formulation development; Manufacturing/blinding, packaging, randomized labelling and distribution of clinical supplies; Clinical trial technology solutions based on IVRS, Web and EDC; Commercial scale manufacture and distribution; Comprehensive analytical services; EU import testing and QP release for clinical and commercial product.

Philippe's practice over the past twenty-five years has focused on litigation and licensing of intellectual property rights, trade secret and employee non-compete litigation, technology transfer transactions, and the negotiation of patent and trademark contracts and agreements. He has been trial counsel before various federal and state courts, and the International Trade Commission in a diverse range of cases involving pharmaceutical chemistry, classical chemistry, drug delivery systems, medical imaging and injector devices, cardiac pacemakers, and in biotechnology. Philippe has also developed in-house patent programs and contributed to the development of corporate IP strategies, and has been involved in numerous international mergers and acquisitions and directed extensive due diligence projects, and IP portfolio valuations.

Aquapharm Biodiscovery is the UK's premier marine biotechnology company, pioneering the discovery and development of novel bioactives & innovative production systems from marine microbes. The company has a substantial collection of unique marine bacteria and fungi (> 6,500) isolated from diverse and extreme environmental habitats. Through the use of proprietary technology, Aquapharm derives and develops new biologically active natural products from this collection, which have commercial applications in the nutraceutical, cosmeceutical and pharmaceutical sectors. Aquapharm focuses on the development of anti-infectives, anti-inflammatories, natural carotenoids and anti-oxidants through innovative fermentation based technology.

As a mid-sized European CRO we offer the full range of services in the development and conduct of clinical trials across the whole of Central, Eastern & Western Europe (clinical research, data management, biostatistics, medical writing and study drug management incl. QP release). Through our offices in Berlin, Vienna, Gliwice and Budapest, our multi-national professionals deliver highest quality in accordance with ICH-GCP, local, national and international legislation. Our customer-focus, reliability and responsiveness have led to stable and continuous growth over the past years. The Assign Group stands for tailor-made solutions in clinical research.

BioQuanta offers biopharmaceutical companies expert molecular modelling capabilities for design, validation and optimization of compounds and screened molecule libraries. Partnering with hospital laboratories, we offer a comprehensive approach combining in-silico and NMR with in-vitro and in-vivo experimental data generation. Our gold standard service relies on standardized quantum chemistry, molecular dynamics protocols and proprietary software tools that enable rationalization of highly reliable structure-activity prediction for proteins and receptors, target identification for a given effect, lead optimization and toxicity prediction. The fast delivery of reliable data on a drug and its interaction mechanisms with its target saves time and resources while reducing risks of failure during clinical development. Such data is required to regulatory approval for new drug application filing

BioSciences Research Institute (BRI) has been setup as a premier Institute for conducting Research and Advanced Training, in the field of BioSciences. The institute has been promoted as a Not-for-Profit organization for promoting the growth of BioSciences in India. The aim and vision of the institute is to provide a platform for individuals, professionals, R&D Organizations, Pharmaceutical & Software companies to utilize and harness the Indian biotechnology Potential. BRI is engaged in Bioinformatics Training, Research and Development, Offshore R&D Support and Bio utilities simulation and development. Our R&D Team specializes in improving and inventing techniques, methodologies and environments for research in Biotechnology.

Cellectricon is a key innovator and solutions provider of advanced cell-based screening products to accelerate biotechnology and drug discovery. Cellectricon's cell-based screening solutions and product pipeline are aimed at critical bottlenecks in the drug discovery where today's products are inadequate. The company's launched products has received outstanding market acceptance including 9 of the 10 largest pharmaceutical companies. At Bio-Europe Cellectricon will present their cutting-edge screening systems that will transform drug discovery:

–Cellaxess-HT – The world's first high throughput RNAi screening system

–Dynaflow-HT – Next generation high throughput APC system for ion channel screening

Clean Cells is a French CRO offering a comprehensive biosafety testing program of in vitro and in vivo services supporting the process development of bioproducts (recombinant proteins, monoclonal antibodies, vaccines, cell and gene therapy products…) from initial R&D stages through clinical trials. Clean Cells has at its disposal over 4300 square feet of laboratory space in full compliance with American and European Pharmacopeia regulatory specifications at biosafety level II and III. This state of the art facility is designed to meet all requirements for biosafety controls (mycoplasma, sterility, viruses, residual DNA, endotoxins…) and cell characterization (isoenzymes, DNA finger printing, karyology...) Clean Cells differs from its larger competitors in its ability to offer very personalized services to its customers with a fast response time at a competitive cost.

Cobra Biomanufacturing is a company focused on a solution-led approach to biomanufacturing for the production of biopharmaceuticals, including recombinant proteins, protein conjugation, virus and plasmid DNA products up to Phase III. The company provides world-class process development solutions, cGMP contract manufacturing and a high level of analytical capabilities for the development of products from pre-clinical evaluation through to clinical trial manufacture. Cobra has an international base with major accounts in Europe, the U.S., Africa and Australasia. Our mission is to work in partnership with our customers to accelerate the clinical development of their products and to add significant value to their business.

Eden Biodesign is a world leader in the provision of biopharmaceutical development and manufacturing expertise and now operates the new world class UK National Biomanufacturing Centre. The combination of the advanced facility and the expertise found in its people, mean